相关实验视频
Updated: Jan 16, 2026

07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
1.0K
在类风湿性关节炎中先进的免疫调节:免疫检查点,微RNA和基于细胞的疗法
Sandra Pascual-García1, Raúl Cobo1, José Luis Bolinches1
1Department of Biotechnology, University of Alicante, 03690 San Vicente del Raspeig, Spain.
Biomedicines
|September 27, 2025
概括
新兴的免疫调节策略,如免疫检查点,microRNAs (miRNAs) 和细胞疗法,对治疗类风湿性关节炎 (RA) 是有前途的. 综合性方法与奥米克技术相结合,可能导致个性化的RA免疫疗法.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 翻译医学是一种翻译医学.
背景情况:
- 类风湿性关节炎 (RA) 是一种慢性自身免疫性疾病,其特点是关节炎症和破坏.
- 目前的向疗法面临的挑战是治疗反应的可变性和耐药性.
- 需要新的免疫调节策略来改善RA管理.
研究的目的:
- 批判性地评估对于类风湿性关节炎 (RA) 的新兴免疫调节策略.
- 专注于免疫检查点,微RNA (miRNA) 和基于细胞的疗法.
- 评估它们作为诊断和治疗工具的潜力.
主要方法:
- 关于RA免疫调节的最近研究的非系统性文献综述.
- 免疫检查点路径 (CTLA-4,PD-1/PD-L1,ICOS) 的分析.
- 检查基于miRNA的干预措施和基于细胞的疗法.
主要成果:
- 免疫检查点调节显示在减少炎症和恢复耐受性方面具有临床前的有效性.
- miRNAs显示出作为生物标志物和治疗药物的潜力,通过外体细胞递送来增强.
- 基于细胞的疗法显示出具有良好的安全性的免疫调节作用.
- 综合策略表现出协同效应,特别是当它们以分子分析为指导时.
结论:
- 有针对性的免疫调节,包括细胞疗法,检查点抑制和miRNA操纵,将彻底改变RA治疗.
- 与omics技术的整合可以提高个性化免疫疗法的精度和安全性.
- 多学科,以患者为中心的方法对于推进个性化RA免疫疗法至关重要.
相关概念视频
T Cell Types and Functions
2.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.2K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
The JAK-STAT Signaling Pathway
12.1K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
12.1K
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
492
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
492
Inflammatory Bowel Disease IV: Pharmacological Management
521
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
521

